EPZM - EPZM STOCK NEWS

Epizyme reported Q3 2021 financial results with net product revenues of $5.2 million, a 22% increase in end user demand, driven by sales in Follicular Lymphoma. The company received a $25 million upfront payment from HUTCHMED's licensing agreement. Ongoing studies include the SYMPHONY-1 Phase 1b/3 trial and the EZM0414 SETD2 inhibitor, which has received fast-track status. Cash and equivalents totaled $221.3 million, with expected non-GAAP operating expenses between $220-$230 million for 2021.

Epizyme (EPZM) has announced the approval of equity awards for a new employee, effective November 1, 2021. The employee will receive options to purchase 42,500 shares of common stock at an exercise price of $4.44, along with 28,333 restricted stock units (RSUs). These options and RSUs will vest over two years, contingent on the employee's continued employment. This decision aligns with Nasdaq Listing Rule 5635(c)(4) regarding inducement awards. Epizyme continues its mission in developing epigenetic therapies, including its FDA-approved product, TAZVERIK.

Epizyme, Inc. (Nasdaq: EPZM) announced that the FDA has granted Fast Track designation for its investigational oral SETD2 inhibitor, EZM0414, aimed at treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company also initiated a Phase 1/1b study to assess the drug's safety and optimal dose. The trial will focus on both DLBCL and multiple myeloma, particularly the high-risk t(4;14) mutation. This designation aims to expedite drug development and enhance patient access to innovative therapies for serious diseases.

Epizyme, a commercial-stage biopharmaceutical company, will host a conference call on November 9, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results and provide a business update. The call can be accessed at (877) 844-6886 for domestic callers and (970) 315-0315 for international participants. A live webcast will also be available on their website. Epizyme focuses on developing epigenetic therapies, currently offering one FDA-approved product, TAZVERIK®, for specific cancer indications.

Epizyme has launched In My Blood, an online resource aimed at empowering patients with follicular lymphoma in their treatment journey. The platform features My Follicular Lymphoma Coach, a unique personalized quiz that guides patients based on their disease stage and symptoms. It offers tools for developing proactive healthcare discussions, symptom trackers, and success stories from patients. This initiative highlights the significance of the patient-provider relationship in managing this typically incurable cancer, impacting approximately 14,800 new cases annually in the U.S.

Epizyme (NASDAQ: EPZM) announced the approval of equity awards for a new employee, effective October 1, 2021, as per Nasdaq Listing Rule 5635(c)(4). The employee received options to purchase 125,866 shares of common stock at an exercise price of $5.19, equal to the stock's closing price on the grant date. Additionally, 25,289 restricted stock units (RSUs) were awarded. The vesting schedule includes a 50% vesting on the first anniversary and the remaining on the second anniversary, contingent upon continued employment.

Epizyme, Inc. (NASDAQ: EPZM) announced two poster presentations for Tazemetostat at the 2021 ESMO Virtual Congress, scheduled from September 16-21, 2021. One poster will update safety data from the EZH-1101 study in prostate cancer, showing durable responses in patients. The second will discuss Tazemetostat's combinations in treating solid tumors. The ongoing studies suggest a promising profile for Tazemetostat, with no new safety signals reported and over one-third of patients enrolled in the randomized portion of the prostate cancer study.

Epizyme (Nasdaq: EPZM) has granted equity inducement awards to two new employees, totaling 80,000 options and 53,333 restricted stock units (RSUs). The options have an exercise price of $5.31, matching the closing price on the grant date, August 16, 2021. Vesting will occur in two tranches over two years, contingent on ongoing employment. Epizyme is focused on developing epigenetic therapies for cancer, with FDA-approved TAZVERIK® for specific cancers, and continues exploring its potential across other malignancies.

Epizyme, Inc. (Nasdaq: EPZM) announced a CEO succession plan, effective August 9, 2021, with Grant Bogle succeeding Robert Bazemore as President and CEO. Bazemore transitions to a consultancy role for one year. Bogle, a board member since 2019, aims to expand TAZVERIK's commercial adoption while advancing the company's pipeline. He brings significant experience in oncology and commercial markets. This leadership change underscores the company's commitment to growing its novel epigenetic therapies and maximizing TAZVERIK's potential in treating epithelioid sarcoma and follicular lymphoma.